Compositions and methods relating to salts of specialized pro-resolving mediators
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-047/54
A61K-031/202
A61K-031/232
A61K-047/62
A61P-001/06
A61P-001/12
A61P-001/04
A61P-001/00
A61P-029/00
A61K-038/03
A61K-045/06
출원번호
US-0535936
(2017-06-02)
등록번호
US-10130719
(2018-11-20)
국제출원번호
PCT/US2017/035752
(2017-06-02)
국제공개번호
WO2017/210604
(2017-12-07)
발명자
/ 주소
Sciavolino, Frank C.
Mathias, Gary
Van Zandt, Michael C.
Jagdmann, Jr., Gunnar Erik
Dworak, Jessica J.
출원인 / 주소
Thetis Pharmaceuticals LLC
대리인 / 주소
Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
인용정보
피인용 횟수 :
0인용 특허 :
65
초록▼
The present invention relates to compounds which are salts of specialized pro-resolving mediators (referred to herein as “SPMs”) which include lipoxins, resolvins, protectins, and their aspirin-triggered counterparts. The SPM salts described here contain at least one or two SPM molecules ionically b
The present invention relates to compounds which are salts of specialized pro-resolving mediators (referred to herein as “SPMs”) which include lipoxins, resolvins, protectins, and their aspirin-triggered counterparts. The SPM salts described here contain at least one or two SPM molecules ionically bound to at least one basic function that is provided by a scaffold moiety as described herein, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.
대표청구항▼
1. A compound of Formula IV which contains a scaffold of two amino acid moieties coordinated around a divalent metal and one or two SPM molecules A, B, ionically bound to at least one basic function provided by the scaffold: whereinM is a divalent metal selected from magnesium (Mg2+), calcium (Ca2+)
1. A compound of Formula IV which contains a scaffold of two amino acid moieties coordinated around a divalent metal and one or two SPM molecules A, B, ionically bound to at least one basic function provided by the scaffold: whereinM is a divalent metal selected from magnesium (Mg2+), calcium (Ca2+), and zinc (Zn2+),A and B are each independently an SPM molecule selected from the group consisting of resolvins and their aspirin-triggered counterparts,A and B may be the same or different,either A or B, but not both, may be absent,R1 and R2 are each independently —(CH2)3—Y1, and —(CH2)4—Y2, where Y1 and Y2 are each a basic function selected from a positively charged primary amine, a positively charged secondary amine, a positively charged tertiary amine, and a positively charged guanidine,X1 and X2 are each independently H or CO—Z and Z is a peptide comprising 1 to 5 amino acids. 2. The compound of claim 1, wherein M is selected from magnesium (Mg2+) or calcium (Ca2+). 3. The compound of claim 1, wherein R1 and R2 are each —(CH2)4—Y2 and Y2 is —NH3+. 4. The compound of claim 1, wherein X1 and X2 are each H. 5. The compound of claim 1, wherein A and B are the same and selected from the group consisting of RvD1, RvD2, RvE1, AT-RvD1, AT-RvD2, and AT-RvE1. 6. The compound of claim 5, wherein A and B are RvE1. 7. The compound of claim 5, wherein A and B are AT-RvE1. 8. The compound of claim 1, which is selected from the group consisting of bis RvE1 magnesium di-lysinate (bis RvE1-Mg-lys-lys), bis RvE1 calcium di-lysinate (bis RvE1-Ca-lys-lys), bis RvE1 zinc di-lysinate (bis RvE1-Zn-lys-lys), bis AT RvE1 magnesium di-lysinate (bis AT(18S)-RvE1-Mg-lys-lys), bis AT RvE1 calcium di-lysinate (bis AT(18S)-RvE1-Ca-lys-lys), and bis AT RvE1 zinc di-lysinate (bis AT(18S)-RvE1-Zn-lys-lys). 9. A pharmaceutical composition comprising the compound of claim 1, and a carrier or excipient. 10. The pharmaceutical composition of claim 9, formulated as an oral or rectal dosage form. 11. A method for treating inflammation in a subject in need thereof, the method comprising administering to the subject the compound of claim 1. 12. A method for treating a disease or disorder selected from ulcerative colitis, Crohn's disease, proctitis, pouchitis, Crohn's disease of the pouch, eosinophilic colitis, lymphocytic colitis, collagenous colitis, diversion colitis, chemical colitis, and ischemic colitis in a subject in need thereof, the method comprising administering to the subject the compound of claim 1. 13. A method for treating a disease or disorder selected from eosinophilic esophagitis, Behcet's disease, irritable bowel syndrome, Celiac disease, intestinal mucositis, diverticulitis, and short bowel syndrome in a subject in need thereof, the method comprising administering to the subject the compound of claim 1. 14. A method for treating ulcerative colitis, Crohn's disease, or pouchitis in a subject in need thereof, the method comprising administering to the subject the compound of claim 1. 15. A method of making a compound of claim 1, the method comprising contacting a solution of the SPM in a nonaqueous solvent with an amount of magnesium, calcium, or zinc di-lysinate, such that the molar amount of the SPM to the metal di-lysinate is about 2:1. 16. The method of claim 15, wherein the solution further comprises an antioxidant, preferably tocopherol. 17. The method of claim 13, wherein the disease or disorder is eosinophilic esophagitis. 18. The compound of claim 1, wherein A and B are both present and each is RvE1,R1 and R2 are each —(CH2)4—Y2,Y2 is —NH3+, andX1 and X2 are each H. 19. The compound of claim 18, wherein M is magnesium and the compound is designated bis RvE1 magnesium di-lysinate (bis RvE1-Mg-lys-lys). 20. A pharmaceutical composition comprising the compound of claim 19, and a carrier or excipient. 21. A method for treating ulcerative colitis in a subject in need thereof, the method comprising administering to the subject the compound of claim 19, or the pharmaceutical composition of claim 20. 22. A method for treating Crohn's disease in a subject in need thereof, the method comprising administering to the subject the compound of claim 19, or the pharmaceutical composition of claim 20. 23. A method for treating pouchitis in a subject in need thereof, the method comprising administering to the subject the compound of claim 19, or the pharmaceutical composition of claim 20. 24. A method for treating eosinophilic esophagitis in a subject in need thereof, the method comprising administering to the subject the compound of claim 19, or the pharmaceutical composition of claim 20. 25. The compound of claim 18, wherein M is calcium or zinc. 26. A pharmaceutical composition comprising the compound of claim 25, and a carrier or excipient. 27. A method for treating ulcerative colitis in a subject in need thereof, the method comprising administering to the subject the compound of claim 25, or the pharmaceutical composition of claim 26. 28. A method for treating Crohn's disease in a subject in need thereof, the method comprising administering to the subject the compound of claim 25, or the pharmaceutical composition of claim 26. 29. A method for treating pouchitis in a subject in need thereof, the method comprising administering to the subject the compound of claim 25, or the pharmaceutical composition of claim 26. 30. A method for treating eosinophilic esophagitis in a subject in need thereof, the method comprising administering to the subject the compound of claim 25, or the pharmaceutical composition of claim 26.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (65)
Ashmead Harvey H. (Kaysville UT) Ashmead H. Dewayne (Fruit Heights UT) Graff Darrell J. (Ogden UT), Amino acid chelated compositions for delivery to specific biological tissue sites.
Goodman,Daniel W.; Hanley,Michael R.; Bursten,Stuart L.; Serhan,Charles N., Analogues of lipid mediators derived from omega-3 PUFAs and methods of use.
Goodman, Daniel W.; Hanley, Michael R.; Bursten, Stuart L.; Serhan, Charles N., Analogues of lipid mediators derived from ω-3 PUFAs and methods of use.
Osterloh, Ian; Wicker, Pierre; Braeckman, Rene; Soni, Paresh; Manku, Mehar, Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy.
Glonek Thomas (803 Highland Ave. Oak Park IL 60304) Greiner Jack V. (208 Stearns Hill Rd. Waltham MA 02154) Korb Donald R. (10 Brimmer St. Boston MA 02108), Dry eye treatment solution and method.
Chang, Han-Ting; Charmot, Dominique; Glinka, Tomasz; Cope, Michael James; Goka, Elizabeth; Shao, Jun; Cartigny, Damien; Chen, Shiah-yun; Buysse, Jerry M., Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors.
Kim, Sung Wuk; Jun, Sung Soo; Jo, Young Gwan; Koo, Ja Seong; Kim, Young Woong, N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same.
Kim, Sung Wuk; Jun, Sung Soo; Jo, Young Gwan; Koo, Ja Seong; Kim, Young Woong; Kim, Byoung Ha; Kim, Duck, N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same.
Yves Bonhomme FR; Philippe Briet FR, Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.